medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2016, Number 2

<< Back Next >>

Ann Hepatol 2016; 15 (2)

Alkaline phosphatase normalization is a biomarker of improved survival in primary sclerosing cholangitis

Hilscher M, Enders FB, Carey EJ, Lindor KD, Tabibian JH

Language: English
References: 21
Page: 246-253
PDF size: 162.46 Kb.


ABSTRACT

Introduction. Recent studies suggest that serum alkaline phosphatase may represent a prognostic biomarker in patients with primary sclerosing cholangitis. However, this association remains poorly understood. Therefore, the aim of this study was to investigate the prognostic significance and clinical correlates of alkaline phosphatase normalization in primary sclerosing cholangitis. Material and methods. This was a retrospective cohort study of patients with a new diagnosis of primary sclerosing cholangitis made at an academic medical center. The primary endpoint was time to hepatobiliaryneoplasia, liver transplantation, or liver-related death. Secondary endpoints included occurrence of and time to alkaline phosphatase normalization. Patients who did and did not achieve normalization were compared with respect to clinical characteristics and endpoint-free survival, and the association between normalization and the primary endpoint was assessed with univariate and multivariate Cox proportional-hazards analyses. Results. Eighty- six patients were included in the study, with a total of 755 patient-years of follow-up. Thirty-eight patients (44%) experienced alkaline phosphatase normalization within 12 months of diagnosis. Alkaline phosphatase normalization was associated with longer primary endpoint-free survival (p = 0.0032) and decreased risk of requiring liver transplantation (p = 0.033). Persistent normalization was associated with even fewer adverse endpoints as well as longer survival. In multivariate analyses, alkaline phosphatase normalization (adjusted hazard ratio 0.21, p = 0.012) and baseline bilirubin (adjusted hazard ratio 4.87, p = 0.029) were the only significant predictors of primary endpoint-free survival. Conclusions. Alkaline phosphatase normalization, particularly if persistent, represents a robust biomarker of improved long-term survival and decreased risk of requiring liver transplantation in patients with primary sclerosing cholangitis.


REFERENCES

  1. Tabibian JH, Lindor KD. Primary sclerosing cholangitis: a review and update on therapeutic developments. Expert review of gastroenterology &hepatology 2013; 7: 103-14.

  2. Gupta A, Bowlus CL. Primary sclerosing cholangitis: etiopathogenesis and clinical management. Frontiers in bioscience 2012; 4: 1683-705.

  3. Levy C, Lindor KD. Primary sclerosing cholangitis: epidemiology, natural history, and prognosis. Seminars in liver disease 2006; 26: 22-30.

  4. Tabibian JH, O’Hara SP, Splinter PL, Trussoni CE, Larusso NF. Cholangiocyte senescence via N-Ras activation is a characteristic of primary sclerosing cholangitis. Hepatology2014; 7: 103-14.

  5. Tabibian JH, Lindor KD. Challenges of Cholangiocarcinoma Detection in Patients with Primary Sclerosing Cholangitis. Journal of Analytical Oncology 2012;1: 50-5.

  6. Karlsen TH, Schrumpf E, Boberg KM. Update on primary sclerosing cholangitis. Digestive and liver disease 2010; 42: 390-400.

  7. Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P. The natural history of nonalcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 2009; 58: 1538-44.

  8. Tabibian JH, Enders F, Imam MH, Kolar G, Lindor KD, Talwalkar JA. Association between serum IgE level and adverse clinical endpoints in primary sclerosing cholangitis. Ann Hepatol 2014; 13: 384-9.

  9. Kim WR, Therneau TM, Wiesner RH, Poterucha JJ, Benson JT, Malinchoc M, LaRusso NF, et al. A revised natural history model for primary sclerosing cholangitis.Mayo Clinic proceedings 2000; 75: 688-94.

  10. Wiesner RH. Moving toward evidence-based liver allocation in patients with primary sclerosing cholangitis.Liver transplantation 2013; 19: 241-2.

  11. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D’Amico G, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-70.

  12. Olsson R, Broome U, Danielsson A, Hägerstrand I, Järnerot G, Lööf L, Prytz H, et al. Spontaneous course of symptoms in primary sclerosing cholangitis: relationships with biochemical and histological features. Hepatogastroenterology 1999; 46: 136-41.

  13. Balasubramaniam K, Wiesner RH, LaRusso NF. Primary sclerosing cholangitis with normal serum alkaline phosphatase activity.Gastroenterology 1988; 95: 1395-8.

  14. Stanich PP, Bjornsson E, Gossard AA, Enders F, Jorgensen R, Lindor KD. Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Digestive and liver disease 2011; 43: 309-13.

  15. Tabibian JH, Weeding E, Jorgensen RA, Petz JL, Keach JC, Talwalkar JA, Lindor KD. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study. Alimentary pharmacology & therapeutics 2013; 37: 604-12.

  16. Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ. Diagnosis and management of primary sclerosing cholangitis.Hepatology 2010; 51: 660-78.

  17. Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis).VirchowsArchiv 1978; 379: 103-12.

  18. NguJH, Gearry RB, Wright AJ, Stedman CA. Inflammatory bowel disease is associated with poor outcomes of patients with primary sclerosing cholangitis. Clinical gastroenterology andhepatology 2011; 9: 1092-7; quiz e135.

  19. Al Mamari S, Djordjevic J, Halliday JS, Chapman RW. Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 2013; 58: 329-34.

  20. Corpechot C, Gaouar F, El Naggar A, Kemgang A, Wendum D, Poupon R, Carrat F, et al. Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis. Gastroenterology 2014; 146: 970-9; quiz e15-6.

  21. Tabibian JH, Lindor KD. Ursodeoxycholic acid in primary sclerosing cholangitis: if withdrawal is bad, then administration is good (right?). Hepatology 2014; 60: 785-8.




2020     |     www.medigraphic.com